Find Funding Opportunities

Purpose. Participating Institutes and Centers (ICs) of the National Institutes of Health (NIH) invite applications for R01 awards to support Bioengineering Research Partnerships (BRPs) for basic, applied, and translational multi-disciplinary research that addresses important biological, clinical or biomedical research problems. In the context of this program, a partnership is a multi-disciplinary research team, that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. The partnership must operate according to a clear leadership plan and include appropriate bioengineering or allied quantitative sciences in combination with biomedical and/or clinical components. BRPs may propose, within a 12-page research strategy section, design-directed, developmental, discovery-driven, or hypothesis-driven research at universities, national laboratories, medical schools, large or small businesses, or other public and private entities or combinations of these entities, and will be evaluated against expanded review criteria. It is expected that a BRP will have a well-defined goal or deliverable that will be achieved in a 5-10 year timeframe based on objective milestones specified in the initial application. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Budget and Project Period. Because the

Purpose. This Funding Opportunity Announcement (FOA) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Deafness and Other Communication Disorders (NIDCD) encourages Research Project Grant (R01) applications from institutions/ organizations that propose research relevant to the basic understanding and development of therapeutic interventions for currently screened conditions and high priority genetic conditions for which screening could be possible in the near future. In this FOA, a high priority condition is one for which the development of an efficacious therapy would make the condition amenable to newborn screening. Mechanism of Support. This FOA will utilize the R01 funding mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-10-231 and PAR-10-232 that encourage applications under the R03 and R21 mechanisms (FOA numbers/URLs). Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

Purpose: The purpose of the Neurological Academic Development Award (K12) is to facilitate and support the career development of pediatric neurologists who have made a commitment to independent research careers. Under this award, newly trained pediatric neurologists are to be selected and appointed to this program by the grantee institution. It is expected that individuals appointed to the NSADA program will subsequently apply for their own Mentored Clinical Scientist Development Award (K08), the Mentored Patient-Oriented Career Development Award (K23), an NINDS Research Scientist Development Award (K02) or a Research Project Grant (R01), Mechanism of Support: This FOA will use the NIH Institutional Research Career Development K12 grant mechanism. K12 programs may not be transferred from one institution to another. (See section VI.2.) This Funding Opportunity Announcement (FOA) will utilize the Mentored Clinical Scientist Development Institutional Program Award (K12) mechanism. The NINDS K12 program provides support for up to three years of supervised study and research for clinically trained professionals who have the potential to develop into productive, clinical investigators. Funds Available and Anticipated Number of Awards: Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.

Purpose. This funding opportunity announcement (FOA) invites applications proposing highly innovative research that will investigate the epigenetic basis of human diseases. These studies will discover and define epigenetic marks or features and their possible interactions in cells and tissues that are representative of various human disease states, conditions or processes. Studies may also investigate the mechanism by which epigenetic changes occur in diseased or otherwise compromised states, and how these changes result in phenotypic differences. Mechanism of Support. This FOA will utilize the R01 award mechanism. Funds Available and Anticipated Number of Awards. The participating agencies intend to commit a total of $6.7 million. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The anticipated number of awards is 10-15.

Purpose. The purpose of this Funding Opportunity Announcement (FOA), issued by the Office of Research on Womens Health (ORWH) and co-sponsoring NIH institutes and centers (ICs), is to promote innovative, interdisciplinary research that will advance new concepts in womens health research and the study of sex/gender differences. Recent research reports have established the importance of studying issues specific to women, including the scientific and clinical importance of analyzing data separately for females and males. ORWH is particularly interested in encouraging extramural investigators to undertake new interdisciplinary research to advance studies on how sex and gender factors affect women's health; however, applications in all areas of womens health and/or sex/gender research are invited. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) award mechanism. Funds Available and Anticipated Number of Awards. It is anticipated that $4 million will be available for FY 2011. The total amount awarded and the number of awards will depend upon the number, quality, and costs of the applications received. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Purpose. This FOA is issued as an initiative of the NIH Blueprint for Neuroscience Research. The Neuroscience Blueprint is a collaborative framework through which 16 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). The goal of this FOA is to facilitate the partnering of pain scientists and non-pain neuroscientists from the field of neural plasticity to capture insights and expertise from disciplines where transitions from health to disease have been extensively examined. An expected outcome of this FOA will be the formation of partnerships between pain researchers and non-pain neuroscientists to develop new collaborations focused on understanding the maladaptive neuroplastic changes that occur during the transition from acute to chronic pain. It is anticipated that these initial collaborations will lead to new applications for highly innovative projects centered on similar studies of the transition from acute to chronic pain. The purpose of this FOA is to encourage the submission of competitive revision applications that propose a collaborative, one year pilot study or a new specific aim associated with an active NIH grant. The parent grant may be focused on pain or on neural plasticity outside the area of pain. Mechanism of Support. This FOA will utilize the Competitive Revision grant mechanism for R01 applications. Funds Available and Anticipated Number of Awards. The participating Neuroscience Blueprint Institutes intend to commit at least $375,000 in 2011 (and at least an additional $375,000 per year in 2012 and 2013 to fund approximately 5-6 Competitive Revisions in response to this FOA. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for submitting grant applications for investigator-initiated, multi-site, randomized, controlled Phase III clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials may address any research question related to the mission and goals of the NINDS. Information about the mission, strategic plan and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/). This FOA is not intended for support of single-center studies or multi-center observational studies that are not testing an intervention. NINDS requires the submission of separate applications for the Clinical Coordinating Center (CCC) and the Data Coordinating Center (DCC). Separate applications for core functions (e.g., quality of life/economic analyses, imaging centers) may be submitted, but are not required. This FOA is to be used for the submission of each component (see Section IV. for instructions).

Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for submitting grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address research questions related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or surgical, behavioral or rehabilitation therapies. Information about the mission, strategic plans and research interests of the NINDS can be found at the NINDS website (http:\\www.ninds.nih.gov). Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds. The total amount awarded and the number of awards will depend upon the impact, quality, number, duration, and cost of the applications received.

Purpose. This FOA is issued as an initiative of the NIH Blueprint for Neuroscience Research.The Neuroscience Blueprint is a collaborative framework through which 16 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). The goal of this FOA is to facilitate research collaborations between pain scientists and non-pain neuroscientists with expertise in neuroplasticity in order to study biological mechanisms underlying the transition from acute to chronic pain. These collaborations will capture insights and expertise from disciplines where transitions from health to disease have been extensively examined. The purpose of this FOA is to encourage submission of multi-PI grant applications that propose highly collaborative, multidisciplinary research projects addressing neuropathic pain conditions. An expected outcome of this FOA will be the formation of partnerships between pain researchers and non-pain neuroscientists to develop new collaborations focused on understanding the maladaptive neuroplastic changes that occur during the transition from acute to chronic neuropathic pain. Mechanism of Support. This FOA will utilize the R01 award mechanism. Funds Available and Anticipated Number of Awards. The participating Neuroscience Blueprint Institutes intend to commit $5 million in 2011 to fund approximately 7-10 awards in response to this FOA. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Budget and Project Period. Direct costs appropriate for the project and a project duration of up to five years may be requested.

Purpose. The National Institutes of Health (NIH) announces a unique opportunity for investigators working with molecular probe compounds to gain access to a robust virtual pharma drug development network to develop neurotherapeutic drugs. Successful applicants to this initiative will be collaborative participants in this network, receiving both funding and no-cost access to contracted drug development services that are not typically available to the NIH-funded research community. Funding will be provided through a U01 cooperative agreement to conduct biological testing of compound analogs in disease assays and models in the investigators laboratory. No-cost drug development services will also be provided, including medicinal chemistry optimization, IND-directed pharmacology and toxicology, and Phase I clinical testing. Researchers who have disease assays and small molecule compounds that show promise for treating nervous system and psychiatric disorders, but that are not yet suitable for clinical testing, are strongly encouraged to apply. Investigators funded through this FOA will be active partners in the design and implementation of the drug development strategy in collaboration with an NIH-appointed advisory panel of drug development experts. This program is structured to allow investigators to maintain control of the intellectual property generated using their assays and starting compounds and to pursue commercialization of compounds that are developed within the program. This program was established by the NIH Blueprint for Neuroscience and will consider applications for nervous system disorders within the missions of any of the 16 participating NIH Institutes (http://neuroscienceblueprint.nih.gov/blueprint_basics/about_blueprint.h…). Disorders of interest include, but are not limited to, neurological, psychiatric and developmental disorders, dementias of aging, diseases and disorders of the eye or ear, and drug and alcohol dependence and addiction. By initiating development of up to 20 new small-molecule compounds over two years, we anticipate that approximately four compounds will enter Phase 1 clinical trials within this program. The ultimate goals of this Neurotherapeutics Grand Challenge are to produce at least one novel and effective drug for a nervous system disorder that is currently poorly treated and to catalyze industry interest in novel disease targets by demonstrating early-stage success. Mechanism of Support. This FOA will use the NIH Research Project Cooperative Agreement (U01) award mechanism. Funds Available and Anticipated Number of Awards. The participating ICs intend to commit up to $1,750,000 in FY 11 to fund up to 10 awards in the first year of this program. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. It is anticipated that funded projects will carry direct costs of up to $125,000 per year for in vitro and/or in vivo bioactivity screening.